1. Atezolizumab/nivolumab/pembrolizumab
   , 2022, Reactions Weekly CrossRef
2. “It Is So Easy For Them to Dismiss”: A Phenomenological Study of Cancer Survivors With Chronic Cancer-Related Pain
   Katie Fitzgerald Jones et al, 2023, Journal of Palliative Medicine CrossRef